These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12035759)

  • 1. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
    Linde M
    Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). Complications/toxicity of HIV therapy.
    Moore RD; Confrancesco J
    Hopkins HIV Rep; 2005 May; 17(3):1-5, 9. PubMed ID: 16419310
    [No Abstract]   [Full Text] [Related]  

  • 3. The abacavir hypersensitivity reaction and interruptions in therapy.
    Loeliger AE; Steel H; McGuirk S; Powell WS; Hetherington SV
    AIDS; 2001 Jul; 15(10):1325-6. PubMed ID: 11426085
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.
    Boyle BA; Elion R; Cohen CJ; DeJesus E; Hawkins T; Moyle GJ
    AIDS Read; 2007 Oct; 17(10):484-90. PubMed ID: 17990370
    [No Abstract]   [Full Text] [Related]  

  • 5. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartnof HS
    BETA; 1998 Apr; ():49-56. PubMed ID: 11365269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 7. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 8. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 9. Abacavir and cardiovascular risk: reviewing the evidence.
    Costagliola D; Lang S; Mary-Krause M; Boccara F
    Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scientists find some genes a bad omen for anti-HIV drug.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
    [No Abstract]   [Full Text] [Related]  

  • 11. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 12. Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.
    Chaisson RE; Gebo K; Flexner C; Gallant JE; Lucas GM; Bartlett JG
    HIV Clin Trials; 2002; 3(4):333-49. PubMed ID: 12187508
    [No Abstract]   [Full Text] [Related]  

  • 13. Retro Part 2: heartbreaks and STIs (or, remembering Dolly). 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston.
    Mascolini M
    IAPAC Mon; 2003 May; 9(5):96-112. PubMed ID: 12866483
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Brothers C; Cutrell A; Scott T; Hernandez J; Moult A
    Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867
    [No Abstract]   [Full Text] [Related]  

  • 15. [New variations in highly active antiretroviral therapy. Simple combination as a promising option].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():50-2. PubMed ID: 10863312
    [No Abstract]   [Full Text] [Related]  

  • 16. Unusual clinical presentation of hypersensitivity reaction to abacavir.
    Aquilina C; Mularczyk M; Lucas F; Viraben R
    AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198
    [No Abstract]   [Full Text] [Related]  

  • 17. Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). February 22-25, 2005. Complications/toxicity of HIV therapy.
    Moore RD; Cofrancesco J
    HIV Clin Trials; 2005; 6(4):229-34. PubMed ID: 16214738
    [No Abstract]   [Full Text] [Related]  

  • 18. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.